The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Immune-Related Colitis: Diagnosis and Management

Checkpoint inhibitor gastrointestinal toxicity requiring stepwise care

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Onkoloji department. Book Appointment →

What is Immune-Related Colitis: Diagnosis and Management?

Immune-related colitis is inflammation of the colonic and small intestinal mucosa from immune checkpoint inhibitor activation against shared self-antigens.

Incidence is highest with anti-CTLA-4 (ipilimumab) approaching 30 to 40 percent, lower with anti-PD-1/PD-L1 monotherapy and elevated with combination regimens.

Onset typically occurs within 6 to 12 weeks of starting therapy, but can develop at any time including after discontinuation.

Endoscopic findings range from erythema and edema to ulcerations and severe colitis pattern resembling ulcerative colitis or Crohn's disease.

Severity is graded based on stool frequency, abdominal pain, blood per rectum and need for hospitalization or surgical intervention.

Symptoms

Increased frequency of bowel movements over baseline ranging from mild to severe diarrhea.
Bloody stools, mucus or melena suggest more severe inflammation.
Abdominal cramping pain that may be diffuse or localized.
Fever, fatigue and weight loss accompany severe colitis.
Severe complications include bowel perforation, toxic megacolon, dehydration and electrolyte abnormalities.

Risk Factors

Higher rates with anti-CTLA-4 and combination immunotherapy regimens.
Pre-existing inflammatory bowel disease, autoimmune conditions or microscopic colitis.
Prior diarrheal illness or recent antibiotic use altering gut microbiome.
Concurrent NSAID use, older age and higher doses of immunotherapy.
Cancer types receiving combination immunotherapy including melanoma and renal cell carcinoma have higher rates.

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Severe diarrhea with more than 6 stools above baseline, dehydration or signs of hypovolemia requires emergency evaluation.
  • Bloody stools, severe abdominal pain or fever suggest significant colitis needing urgent assessment.
  • Signs of perforation including rigid abdomen, severe pain or hemodynamic instability are surgical emergencies.
  • Persistent diarrhea despite initial corticosteroid therapy indicates need for treatment escalation.
  • Long-term follow-up after colitis recovery monitors for recurrence and chronic gastrointestinal sequelae.

Treatment Methods

01
Grade 1 mild colitis warrants continued therapy with supportive care including hydration and antidiarrheals after infection exclusion.
02
Grade 2 moderate colitis requires holding immunotherapy, corticosteroids (prednisone 1 mg/kg/day) and consideration of resumption upon resolution.
03
Grade 3 to 4 severe colitis necessitates permanent discontinuation of anti-CTLA-4, hospitalization, intravenous methylprednisolone and prompt consideration of biologic therapy if not improving within 3 to 5 days.
04
Infliximab is first-line biologic therapy; vedolizumab is preferred in select cases with reduced systemic immunosuppression effects.
05
Endoscopy with biopsy guides diagnosis; stool studies exclude infection including Clostridium difficile; CMV testing and supportive measures with hydration, electrolyte replacement and gradual corticosteroid taper over 4 to 6 weeks complete management.

Which Department to Visit?

You can visit our Onkoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Onkoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.